Jazz Pharmaceuticals shared a post on LinkedIn:
“H3 K27M-mutant diffuse midline glioma is an ultra-rare, aggressive brain cancer that has historically been marked by limited treatment options and poor prognoses.
Today’s approval represents an important advancement for patients and caregivers impacted by this difficult-to-treat disease by offering them a new treatment option.
The collaborative efforts that culminated in this meaningful achievement showcase our dedication to innovation to help meet the needs of patients and their families.”
More posts featuring Jazz Pharmaceuticals on OncoDaily.